Release Date: January 16, 2012

Expiration Date: January 16, 2013

Case Name

Treatment Options for Non-Small Cell Lung Cancer (NSCLC) in the Second-Line Setting

Discussant

Edward Kim, MD
M. D. Anderson Cancer Center
Houston, Texas, United States

Target Audience

This educational activity is intended for oncologists, pulmonologists, and other healthcare providers involved and/or interested in the management of patients with non-small cell lung cancer (NSCLC).

Overview

This brief case discussion discusses the second-line treatment options for a patient with NSCLC.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

• • Describe appropriate second‐line therapeutic options for metastatic NSCLC, including the use of tyrosine kinase inhibitors


• • Examine the role of bone targeting agents in guiding treatment decisions in advanced NSCLC

Sponsorship

This activity is sponsored by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME^®) to provide continuing medical education for physicians.



prIME Oncology designates this internet-based enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by unrestricted educational grants from Genentech and Celgene Corporation.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.

A link to the post test is available on the post test tab.

Disclosure of Conflicts of Interest

prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Dr Kim has disclosed that he has received consulting fees from Boehringer Ingelheim, Lilly, OSI, and Genentech. He has also performed contracted research for Lilly, Genentech, and OSI.

The employees of prIME Oncology have disclosed:

• • Janelle Bowersox, RN, MSN, OCN (clinical) – no relevant financial relationships to disclose


• • Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose


• • Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose

Disclosure of Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.